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a b s t r a c t
The ability of HIV to establish long-lived latent infection is mainly due to transcriptional silencing of viral
genome in resting memory T lymphocytes. Here, we show that new semi-synthetic ingenol esters reactivate
latent HIV reservoirs. Amongst the tested compounds, 3-caproyl-ingenol (ING B) was more potent in
reactivating latent HIV than known activators such as SAHA, ingenol 3,20-dibenzoate, TNF-α, PMA and
HMBA. ING B activated PKC isoforms followed by NF-κB nuclear translocation. As virus reactivation is
dependent on intact NF-κB binding sites in the LTR promoter region ING B, we have shown that. ING B was
able to reactivate virus transcription in primary HIV-infected resting cells up to 12 fold and up to 25 fold in
combination with SAHA. Additionally, ING B promoted up-regulation of P-TEFb subunits CDK9/Cyclin T1. The
role of ING B on promoting both transcription initiation and elongation makes this compound a strong
candidate for an anti-HIV latency drug combined with suppressive HAART.
& 2014 Elsevier Inc. All rights reserved.
Introduction
The eradication of HIV by current anti-retroviral therapies in
infected individuals is not accomplished due to the establishment
of viral latency during early stages of infection. HIV establishes
long-lived latent infection in resting memory T lymphocytes and
other non-dividing cells mainly due to transcriptional silencing
(Finzi et al., 1997; Geeraert et al., 2008). Despite undetectable viral
load in patients treated with potent antiretroviral therapy, proviral
genomes remain in the latent reservoirs rendering the total
clearance of HIV an unattainable goal at present (Finzi et al.,
1997; Pierson et al., 2000; Yang et al., 2009). Hence, the search for
a cure is one of the most challenging and rewarding areas of
HIV/AIDS research (Geeraert et al., 2008; Johnston, 2010).
Multiple mechanisms contribute to the maintenance of HIV
latency, including integration of the proviral DNA in transcriptionally
inactive sites, Tat trans-activation, histone modiﬁcations or una-
vailability of cellular transcription factors (Ganesh et al., 2003;
Ishida et al., 2006; Jones and Peterlin, 1994; Mbonye and Karn,
2014; Williams et al., 2006). Additionally, post-transcriptional
mechanisms affecting the export or translation of HIV mRNAs
can also block HIV expression during latency (Huang et al., 2007;
Karn and Stoltzfus, 2012; Lassen et al., 2006). HIV activation and
replication is highly dependent on T lymphocyte activation status,
relying on the availability of host transcription factors, such as NF-
κB, NFAT and AP1, which bind to HIV-1 LTR triggering virus RNA
transcription, and others such as P-TEFb that act in transcriptional
elongation (Bartholomeeusen et al., 2013; Contreras et al., 2012,
2007; González et al., 2001; Khalaf et al., 2010; Kinoshita et al.,
1997; Mbonye and Karn, 2014; Sgarbanti et al., 2008; Torgerson
et al., 1998; Yang et al., 1999). Protein kinase C (PKC) activation
followed by NF-κB nuclear translocation is an important step
required for latent HIV reactivation.
The PKC family comprises a large number of serine-threonine
kinases dependent on the hydrolysis of phosphatidyl-inositol-4,
5-bisphosphate (PIP2) for activation. PIP2 is hydrolyzed in diacyl
glycerol (DAG) and inositol-1,4,5-trisphosphate (IP3), promoting
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calcium release from endoplasmic reticulum. This step is impor-
tant to activate PKC calcium dependent isoforms, such as PKC α, βI,
βII, and γ. DAG binds with high afﬁnity to cis-rich zinc ﬁnger
domains in conventional and novel PKC isoforms promoting their
activation (Spitaler and Cantrell, 2004; Steinberg, 2008). In
T lymphocytes, active PKC-θ and PKC-γ stimulate IKK-dependent
phosphorylation and degradation of IκB-α (a NF-κB cellular
inhibitor). Free NF-κB is then able to translocate to the nucleus
and bind to NF-κB responsive promoters stimulating transcription
of several cellular genes, as well as binding to speciﬁc sites in the
LTR region triggering HIV-transcription (Spitaler and Cantrell,
2004; Steinberg, 2008; Williams et al., 2004; Yang et al., 1999).
Several compounds have been investigated as potential candi-
dates for elimination of latent HIV-reservoirs. These, in association
with HAART therapy could potentially eradicate HIV from infected
patients. Therapeutically, anti-latency agents would be given
intermittently or for a limited period of time to purge reservoirs
of dormant HIV. In this scenario, PKC agonists are potential targets
worth exploring (Richman et al., 2009). The phorbol esther PMA
and prostratin reactivate latent HIV in lymphoid and myeloid cells
(Spitaler and Cantrell, 2004; McKernan et al., 2012; Van Lint et al.,
2013; Williams et al., 2004). In a pilot clinical trial, bryostatin
(another modulator of PKC isoforms) has been used to reactivate
HIV from latency (Van Lint et al., 2013).
Histone deacetylase inhibitors (HDACi) have been also tested as
HIV reactivator compounds. SAHA (suberoylanilide hydroxamic acid)
is a histone deacetylases inhibitor that can disrupt HIV-1 latency
in vitro (Archin et al., 2012, 2009; Liu et al., 2006) and in HIV positive
patients submitted to HAART combined with 400 mg of SAHA
(Archin et al., 2012). Introduction of yet another HDACi; valproic
acid (VPA), was envisioned to ﬂush out the latent virus from these
reservoirs within few years, but VPA in combination with HAART
failed to deplete latent HIV reservoir sufﬁciently (Routy et al., 2012).
Some compounds are able to disrupt HIV latency activating the
transcriptional elongation factor b (P-TEFb). This cellular factor can
form two different complexes: an active one, composed by cyclin-
dependent kinase 9 (CDK9) and cyclin T1 (Cyc T1) and an inactive
complex, which in addition to CDK9 and Cyc T1 also contains the
inhibitory protein HEXIM 1 or 2 and the 7SK small nuclear RNA,
amongst other proteins (Cho et al., 2010; Contreras et al., 2009,
2007). Productive transcriptional elongation requires hyper-
phosphorylation of RNA polymerase II C-terminal domain (CTD),
which is accomplished by the CDK9 subunit of active P-TEFb
(Cho et al., 2010). The HMBA (hexamethylene bisacetamide) transi-
ently activates the PI3K/Akt pathway, leading to the phosphorylation
of HEXIM1 and the subsequent release of active P-TEFb, which then
stimulates HIV transcription and reactivation of the latent HIV
reservoir (Contreras et al., 2007). SAHA can also disrupt HIV-1 latency
in vitro and in HAART treated HIV-positive patients (Archin et al.,
2012, 2009; Liu et al., 2006) by transiently turning on the PI3K/Akt
pathway promoting P-TEFb activation (Contreras et al., 2009;
Liu et al., 2006). In resting primary CD4þ T cells, where levels of
P-TEFb are lower, the most potent HDACi, SAHA, has minimal effects.
In contrast, when these cells are treated with a PKC agonist,
bryostatin 1, which increased levels of P-TEFb, then SAHA once again,
reactivated HIV. In this way, HDACis, which can reactivate HIV, work
via the release of free P-TEFb from the 7SK snRNP (Bartholomeeusen
et al., 2013).
While multiple transcriptional regulatory mechanisms for HIV-1
latency have been described in the context of progressive epige-
netic silencing and maintenance, recent reports suggested that
productive infection is positively correlated with cellular activa-
tion and NF-κB activity (Dahabieh et al., 2014). Many natural
compounds are currently been screened for their antiviral proper-
ties and some have been reported as possible candidates for
clinical tests. These include terpenoids, polyphenols and phorbol
esters (Fujiwara et al., 1998; Jassbi, 2006; Salatino et al., 2007). The
diterpene ingenol is a secondary metabolite of Euphorbiacea, a
large family of succulent plants that commonly grow in semi-
desertic areas of Brazil. Ingenol derivates can inhibit HIV reverse
transcription and down modulate CD4 and CXCR4 surface expres-
sion by activating PKC (Ersvaer et al., 2010; Fujiwara et al., 1998;
Hong et al., 2011; Lee et al., 2010; Warrilow et al., 2006).
Additionally, ingenol 3-angelate has anti-tumor activity and acti-
vates responses mediated by PKC pathway, thus being considered
a PKC agonist (Ersvaer et al., 2010; Lee et al., 2010). Another semi-
synthetic derivative, ingenol 3,20-dibenzoate, displays trombo-
poietic activity and also activates PKC pathways (Racke et al.,
2012). In this article, in an attempt to obtain less toxic compounds
retaining anti-latency activities, we synthesized new ingenol
derivates through chemical substitutions in the polyhydroxylated
southern region of ingenol structure, which apparently is critical
for the activity over HIV transcription. The most promising
molecule isolated here, 3-caproyl-ingenol (ingenol B, ING B),
promotes PKC activation and NF-κB nuclear translocation, activat-
ing transcription of B and C HIV-1 subtypes. Finally, ING B induces
higher levels of reactivation when compared to TNF-α, PMA, SAHA
and HMBA, both in established HIV latency models and in HIV
infected primary resting cells.
Results
Screening of ingenol derivates with anti-HIV latency activity
Euphorbia tirucalli latex contains a complex mixture of ingenol
esters. They are mostly esters of dodecatrienic and dodecatetraenic
acids attached at various hydroxyl groups. Alkaline hydrolysis
cleaved the ester bonds producing free ingenol, which was then
isolated in a single chromatographic step. Subsequently, selective
esteriﬁcation at C-3 position produced three new esters of ingenol;
trans-cinnamate (ING A), caprate (ING B), and myristate (ING C)
(Fig. 1A and S1). The primary reason for choosing these ester
groups was to explore initial structure-activity relationship for
various 3-acyl-ingenols for their ability to reactivate latent HIV-1.
We used the J-Lat cell line (clones 6.3 and 8.4), which are derived
T cells that harbor a transcriptionally silent HIV-GFP proviral
genome as a HIV latency model (Jordan et al., 2003).
Cells were exposed to different ingenol derivates and HIV
transcriptional reactivation was evaluated by ﬂow cytometry
measuring GFP expression 24, 48 and 72 h after treatment. In an
initial screening, the original ingenol molecule (ING) activated up
to 35% of J-Lat 6.3 cells at 8 mM; however, only 20% of the cells
were viable at this concentration (Fig. S1A). The modiﬁcations in
the C-3 position of the ING core produced the derivates ING A and
ING C (Fig. 1A). Both of them activated HIV transcription in about
20% of latent cells at 0.32 mM. However, at this concentration these
compounds induced signiﬁcant cytotoxicity (Fig. S1, panels B and D).
ING B ester at the same concentration (0.32 mM) promoted 20% of
HIV activation in the J-Lat 6.3 and 15% of J-Lat 8.4 cells with 100% of
cell viability in both cases (Fig. 1B and C) and no major differences
were observed for the different exposure times suggesting that 24 h
treatment was sufﬁcient to promote HIV transcription (Fig. S1C). The
EC50 for ING B activation was calculated for both J-lat clones (J-Lat
6.3, EC50¼0.13 mM and J-Lat 8.4, EC50¼0.16 mM) with no differences
between these two cells.
All these compounds were compared with TNF-α activation
levels as positive control (Fig. 1B and C, black bars). To conﬁrm the
production of HIV particles by ING B treated cells, their super-
natant was collected after 48 hours and levels of p24 antigen were
measured by ELISA. ING B stimulated virus production to the same
extent as the positive control TNF-α in both J-Lat 6.3 and 8.4 clones
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(Fig. 1D). These results suggested that ING B was able to reactivate
transcription of a latent HIV provirus and induced production of
viral particles. Based on these results we proceeded with further
characterization of this derivate at 0.32–1 mM concentration.
ING B promotes PKC activation and NF-kB translocation to the
nucleus
To evaluate if ING B ester activates PKC, J-Lat cells were pre-
treated with known PKC inhibitors (Gö 6976, Gö 6983 and Ro-31–
8220) and then treated either with PMA, a potent PKC activator, or
with ING B. A similar pattern of HIV activation was found for both
PMA and ING B, suggesting that the latter effect is indeed mediated
by PKC activation in both clones of J-Lat cells (Fig. 2, panels A and B).
Only 3.8%, 1.0% and 0.3% of cells were reactivated by ING B when J-Lat
clone 6.3 was pretreated with PKC inhibitors Gö 6976, Gö 6983 and
Ro-31–8220, respectively (Fig. 2A). Similar results were obtained
with the same PKC inhibitors and ING B treatment in J-Lat clone 8.4
(Fig. 2B) suggesting that PKC activity is modulated by ING B. Neither
cytotoxic effects nor HIV-GFP expression were observed in controls
treated only with PKC inhibitors.
Upon activation, PKCs are translocated to the plasma mem-
brane by RACK proteins (membrane-bound receptor for activated
protein kinase C proteins) (Mochly-Rosen and Gordon, 1998). In
order to verify if ING B is able to promote PKC translocation to the
plasma membrane, HeLa cells expressing PKC isoforms fused to
GFP were treated with ING B or PMA (positive control). Confocal
ﬂuorescence microscopy analysis revealed a diffuse cytoplasmic
PKC-GFP distribution in untreated cells (Fig. 2C, upper panels).
However, 10 min of ING B or PMA treatment were sufﬁcient
to induce translocation of PKCα-GFP, PKCδ-GFP and PKCγ-GFP to
the plasma membrane (Fig. 2C, middle and bottom panels).
Quantiﬁcation analysis showed that 80% of the cells presented
PKC activation in the presence of ING B and PMA (Fig. 2D). This
proﬁle of PKC-GFP sub-membrane localization was maintained up
to 120 min after ING B treatment (Fig. S2). Together, these data
show that ING B acts by promoting PKC activation.
As mentioned before, PKC activation leads to nuclear transloca-
tion of the transcription factor NF-κB due to induction of IKK
degradation in the proteasome (McKernan et al., 2012; Spitaler
and Cantrell, 2004; Williams et al., 2004). The effect of ING B
treatment on nuclear translocation of NF-κB was addressed by two
different approaches. First, using confocal microscopy, the pre-
sence of this transcription factor inside the nucleus of treated HeLa
cells was evaluated using anti-p65 antibodies (Fig. 3A). Levels of
NF-κB translocation were quantiﬁed using the Translocation mod-
ule of MetaXpress software of a High Content Screening confocal
microscope (Molecular Devices, Inc). ING B treatment for 24 h
induced the translocation of NF-κB in 65% of the cells analyzed;
reaching higher values than the positive control with PMA treat-
ment at the same time point (24 h) (Fig. 3B).
The second approach involved the use of LTR-Luciferase repor-
ter assays to quantify NF-κB nuclear function. HIV transcription is
sensitive to NF-κB activation as its promoter carries multiple
copies of the NF-κB recognition sequence. HIV-LTR subtype B
region has two NF-κB binding sites deﬁned by the conserved
sequence GGGACTTTCC (Bachu et al., 2012; Naghavi et al., 1999).
To verify if HIV transcriptional activation by ING B is mediated by
NF-κB binding to the LTR promoter, Jurkat cells were transfected
with pBlue30LTR-Luc (WT) and pBlue30LTR NF-κB MUT-Luc (NF-κB
Fig. 1. Ingenol derivate promotes HIV transcription and virus production. J-Lat cells 6.3 and 8.4 were used as a model of HIV latency. (A) Schematic representation of the
novel ingenol ester derivates from Euphorbia tirucalli. (B) and (C) ING B activates HIV transcription in J-Lat cells, clones 6.3 and 8.4, respectively. Cells were exposed to
increasing concentrations of ING B and virus activation was evaluated by GFP expression using ﬂow cytometer 24 h after treatment (empty bars). Cytotoxicity was measured
using Cell Titer Blue reagent ﬁve days post ING B treatment (black lines) and expressed as viability (%). TNF-α (20 ng/ml) was used as positive control (black bars). Error bars
represent standard deviation of three independent experiments. (D) ING B treatment promotes HIV production. HIV viral particles were evaluated in the supernatants of J-Lat
cells (clones 6.3 and 8.4) exposed to ING B for 48 h by ELISA (HIV-1 p24 Antigen). TNF-α (20 ng/ml) was used as positive control. Mock stands for supernatant of non-treated
cells. Error bars represent standard deviation of three experiments.
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BS) that express the luciferase reporter gene controlled by intact
and mutated NF-κB binding sites, respectively (Dong et al., 2000).
Transfected cells were treated with ING B and transcription
activation was evaluated by luciferase activity. ING B treatment
induced a 10 fold increase in luciferase expression in cells contain-
ing the intact pBlue30LTR-Luc (WT) plasmid (Fig. 3C). As expected,
no difference was observed in the luciferase expression under the
control of mutagenized NF-κB binding sites (NF-κB BS), suggest-
ing that transcriptional activation promoted by ING B is dependent
on intact NF-κB binding site of HIV LTR (Fig. 3C).
Our results show that ING B treatment activates PKC signaling
and NF-κB translocation to the nucleus, activating in turn tran-
scription from the HIV LTR promoter.
LTR from different subtypes of HIV-1 are sensitive to ING B
The LTR promoter region of HIV subtype C contains an extra
NF-κB binding site (GGGGCGTTCC) that differs from the classical
sequence (GGGACTTTCC). Indeed, subtype C of Indian origin
contains a fourth NF-κB binding site (GGGACTTTCT) that has been
associated with higher viral loads in these patients (Bachu et al.,
2012; Dong et al., 2000). In order to check if ING B can activate
virus transcription in the context of both subtype B and C LTRs,
Jurkat cells were transfected with luciferase expression vectors
under the control of LTR promoters from classical subtype B,
harboring two NF-κB binding sites, and from subtype C, containing
3 or 4 NF-κB binding sites.
The two classical NF-kB binding sites were nominated as H, and
the third and fourth NF-κB binding site found in Indian HIV strains
were identiﬁed as C and F, respectively (Fig. 4A). All these versions of
the NF-κB binding site are functional, as described before (Bachu
et al., 2012). The cells were treated with different transcription
activators (ING B, TNF-α and PMA) and the levels of luciferase
expression compared to non-treated cells. All the treatments induced
luciferase expression regardless the subtype origin of the LTR regions
(Fig. 4B). ING B induced higher levels of luciferase expression
compared to TNF-α and PMA in all conditions (Fig. 4B, compare
black with gray bars). Importantly, the LTR region of subtype C har-
boring the forth extra NF-κB binding site (FHHC) was more respon-
sive to ING B treatment than LTR promoters carrying less NF-κB
binding sites, reinforcing the previous results that transcription
activation promoted by this compound is mediated by NF-κB
binding.
These results suggest that ING B elicits activation of HIV
transcription regardless of HIV-LTR subtype and hence could be
used to tackle latency from reservoirs formed by different HIV
subtypes.
Fig. 2. HIV reactivation addressed by ING B is mediated by PKC activation. J-Lat cells were pre-treated with different PKC inhibitors at 1 μM for 24 h (Gö 6976, Gö 6983 and
Ro-31-8220) before ING B addition (0.32 μM). GFP expression was evaluated 24 h post ING B treatment by ﬂow cytometer. PMA (1 μM) was used as positive control of PKC
dependent HIV reactivation. (A) HIV-GFP expression in J-Lat 6.3 cells in the presence of PKC inhibitors. (B) HIV-GFP expression in J-Lat 8.4 cells in the presence of PKC
inhibitors. (C) Analysis of cellular localization of HeLa cells expressing different GFP-tagged PKC isoforms by confocal microscopy. HeLa cells were transfected with expressing
vectors coding PKC-α (left columns), PKC-δ (central columns) and PKC-γ (right columns) and treated with PMA (1 μM) or ING B (0.32 μM) for 10 min. Untreated cells are
labeled as Mock. Cell nuclei are labeled with DAPI (blue color) and PKC-GFP are labeled in green. White arrows are highlighting the sub-membrane location when PKC
isoforms are activated. (D) PKC sub-membrane localization was quantiﬁed in 200 GFP positive cells for each treatment (Mock non-treated, PMA and ING B). PKC-α, PKC-δ and
PKC-γ are represented by black, dark gray and gray bars, respectively. Standard deviation is shown at the top of the bars.
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ING B is the most potent anti-HIV latency drug
We compared the ability of ING B to other previously described
HIV activators in their ability to reactivate HIV from latency.
Initially, J-Lat 6.3 and 8.4 were treated with PMA, prostratin, SAHA
and ingenol 3,20-dibenzoate at the minimum concentration of ING
B capable to produce HIV activation without cytotoxic effects
(0.32 mM). ING B was a superior activator reaching higher levels
of HIV transcription in both clones of J-Lat cells 6.3 (Fig. 5A) and
8.4 (Fig. 5B). SAHA and prostratin had no effect on HIV transcrip-
tion at 0.32 mM (Fig. 5A and B). In J-Lat 6.3 cells, ING B activates up
to 18–20% of the cells, while ingenol 3,20-dibenzoate and PMA
activate 12% of the cells. In J-Lat 8.4 cells, ING B activates up to 14%
of the cells while ingenol 3,20-dibenzoate and PMA activate only
8% and 10%, respectively.
Since SAHA and prostratin did not activate HIV transcription at
0.32 mM, cells were treated with the optimal concentrations
described for these inhibitors (Contreras et al., 2009; Williams
et al., 2004; Wu et al., 2005). Therefore the reactivation levels of ING
B at 0.32 mM were compared to the obtained using higher concentra-
tions of PMA (20 nM), prostratin (10 μM) and SAHA (10 μM) in both
clones, J-Lat 6.3 (Fig. 5C) and 8.4 (Fig. 5D). ING B activated 30% more
cells than SAHA in J-Lat 6.3 cells (Fig. 5C) and the same levels in J-Lat
8.4 cells (Fig. 5D). Here, prostratin treatment reactivated a higher
number of cells from latency compared to ING B in both cell lines,
when used at higher concentrations (10 mM).
These results suggest that ING B is a superior candidate to
promote HIV transcription compared to other HIV activators such
as ingenol 3,20-dibenzoate, SAHA and PMA.
ING B activates HIV transcription in infected primary
resting CD4þ T cells
To expand the results of ING B activation to primary cells, the
levels of transcription activation were evaluated in peripheral
blood mononuclear cells (PBMC) isolated from healthy donors
expressing the luciferase reporter gene under LTR control
(pBlue30LTR-Luc). The ING B treatment promoted potent activation
of luciferase expression in PBMCs from all tested donors (Fig. S3A).
Since PKC activators such as PMA and prostratin are able to
mediate cellular activation, we investigated the effects of ING B
in primary cells activation measuring CD38, HLA-DR and CD69
markers in human lymphocytes. Three different activator com-
pounds were used at 1 mM concentration (ING B, PMA and
prostratin). All of them were able to activate primary cells at this
concentration after 48 h induction (Fig. S3B). ING B activated
primary cells at a higher level than prostratin evidenced by the
induction of early and late activation markers (Fig. S3B). On the
Fig. 3. HIV transcriptional activation by ING B is dependent on NF-κB activation. (A) ING B promotes NF-kB translocation to the nucleus. HeLa cells were treated with ING B
(1 μM) for different time points. After that, the cells were ﬁxed and submitted to immunoﬂuorescence using anti-NF-κB antibodies (red color) and DAPI staining (blue color).
Cells treated with ING B are presented in lower panel and untreated cells (mock) in upper panel. White arrows highlight NF-κB nuclear translocation. (B) Quantiﬁcation of
NF-κB nuclear translocation in HeLa cells, expressed as fold change (FC) at different time points: 1, 6 and 24 h after ING B treatment (1 μM). PMA (1 μM) was used as positive
control (24 h treatment). The fold change was calculated using the average of internalized NF-κB cells of each treatment in comparison to the untreated cells (Mock). 800
HeLa cells were scored and these are results of three independent experiments. (C) Transcription activation by ING B is dependent on intact NF-kB binding site. Jurkat cells
were transfected with pBlue30LTR-Luc (NF-κB WT) and with the construct pBlue30LTR NF-κB MUT-Luc (NF-κB BS) harboring mutations at NF-κB binding sites that prevent its
interaction. After transfections, cells were treated with ING B (0.32 μM). Luciferase assays were performed 24 h post-treatment.
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other hand, PMA demonstrated the highest activation levels at this
concentration when compared to ING B and prostratin.
Resting CD4þ T lymphocytes are the body reservoir of transcrip-
tionally silent HIV in infected individuals, hence these cells are the
best model to evaluate ING B ability to reactivate virus from latency
(Finzi et al., 1997; Geeraert et al., 2008;Bartholomeeusen et al., 2013).
Naïve CD4þ T cells were isolated, activated with anti-CD3/CD28 and
infected with a pseudotyped HIV-1 harboring a luciferase reporter
gene. This virus is defective in the envelope gene and restricted to a
single cycle of replication, which allows the virus to integrate in the
cellular genome and establish latency. After infection, cells were
allowed to return to the resting state by gradually decreasing IL-2
concentration (30– 2 U/ml) over the course of two weeks. The entire
experiment is depicted in the Fig. 6A. The resting state of the cells
was veriﬁed by detection of activator markers (CD38, CD69 and HLA-
DR) by FACS and virus latency was evaluated by measuring luciferase
activity during all IL-2 reduction points (Fig. 6B).
HIV latency was established in all replicates, as conﬁrmed by
the low levels of luciferase expression and reduced activation
markers (CD69, CD38 and HLA-DR) at the lowest concentration of
IL-2 (2 U/ml) (Fig. 6B). At this point cells were treated with ING B,
SAHA or both and the levels of HIV transcription were evaluated
by luciferase expression 24 and 48 h post-treatment (Fig. 6C). The
level of HIV transcription activation was higher with ING B
treatment (up to 12-fold) than with SAHA (Fig. 6C). No differences
of luciferase expression were observed 24 or 48 h post-treatment
either with SAHA or ING B. Indeed, higher levels of HIV activation
were observed when ING B was combined with SAHA (20-fold),
suggesting an additive effect between these different classes of
HIV activators (Fig. 6C).
Several reports suggested that transcription initiation pro-
moted by PKC activation and NF-κB binding is not sufﬁcient for
HIV activation, indicating that transcription elongation is also
required. It is well known that HIV active transcription depends
on P-TEFb activation. In order to verify if ING B exerts some
inﬂuence on the expression of P-TEFb components, naïve T CD4þ
cells were isolated from different healthy blood donors and treated
with 1 mM of ING B. The levels of P-TEFb components (CDK9 and
Cyclin T1) were evaluated by immunoblotting. We observed an
increase in protein levels of both P-TEFb components (CDK9 and
Cyclin T1) in the T CD4þ cells isolated from all donors and treated
with ING B (Fig. 7A). The quantiﬁcation analysis showed the
increase of CDK9 and Cyclin T1 protein levels (up to 2-fold) in
ING B treated T CD4þ compared with non-treated cells (Fig. 7B).
The same analysis was performed with the latent models of HIV
(J-Lat cells), revealing that CDK9 and Cyclin T1 protein levels also
increase in the ING B treated cells (Fig. S4A and B).
To validate our results with another ingenol derivate com-
pound already described as PKC activator, we performed the same
experiments with ingenol 3,20-dibenzoate (DBZ) (Racke et al.,
2012). T CD4þ resting HIV infected cells were treated with DBZ,
SAHA or HMBA alone or in combination. Ingenol 3,20-dibenzoate
was combined with SAHA and HMBA at different concentrations
(Fig. S5A and B). The treatment with ingenol 3,20-dibenzoate
(DBZ) at 20 nM induced the HIV activation at higher levels than
SAHA or HMBA at different concentrations (Fig. S5A and B).
However, ING B induced even higher levels of HIV activation (up
to 12-fold) than ingenol 3,20-dibenzoate (6-fold). The ingenol
3,20-dibenzoate combined with HMBA induced higher levels of
HIV transcription if compared with the same combination with
SAHA (Fig. S5A and B).
The same HIV infected resting cells described above were
treated with ingenol 3,20-dibenzoate and the levels of P-TEFb
components were also evaluated by immunoblotting using anti-
bodies anti-cyclin T1 and CDK9 (Fig. S5C and D). The results
indicate that ingenol 3,20-dibenzoate induced a higher expression
of both P-TEFb components (Cyclin T1 and CDK9).
We thus concluded that ING B is able to activate virus
transcription in HIV reservoirs by promoting both transcription
initiation, mediated by NF-kB nuclear translocation, and increasing
of levels of P-TEFb components, suggesting potential usefulness in
HIV/AIDS cure strategies.
Discussion
In this work we addressed the ability of three new semi-
synthetic ingenol esters, ING A, ING B, and ING C, to reactivate HIV
latency. Chemical modiﬁcations at the C-3 position of ingenol
produced ING B, an ester with the best reactivation/cytotoxicity
proﬁle. This new compound activates the PKC pathway by promot-
ing NF-kB internalization into the nucleus and increasing HIV
transcription, which is dependent on NF-kB binding to LTR
promoter. ING B was also efﬁcient in reactivating HIV transcription
directly in resting T CD4þ cells as primary model of HIV latency.
Ingenol derivates also induced the protein levels of P-TEFb
components (Cyclin T1 and CDK9) that could explain the additive
effect found in activation of HIV when cells were treated with
ingenol in the presence of either SAHA or HMBA.
There are several publications describing anti-cancer activities
of ingenol esters and the HIV transcription activation properties of
Fig. 4. Non-B subtype LTR promoters are also activated by ING B. (A) Schematic
representation of B and C subtype LTR enhancers used. The numbers of NF-κB
binding sites are highlighted in the ﬁgure. The constructs were denominated Null
(without NF-κB binding site), B-LTR (with two canonical NF-κB binding sites), C-LTR
and HHC (both with three NF-κB binding sites) and FHHC-LTR (with four NF-κB
binding sites). All of these LTR regions described were cloned in the same backbone
vector expressing gaussia luciferase. (B) ING B activates luciferase expression
controlled by LTR regions from subtype B and C of HIV-1. Luciferase activity in
fold change of Jurkat cells transfected with the plasmids cited above and treated
with three different activator compounds for 24 h: PMA (1 μM), TNF-α (20 ng/ml)
and ING B (0.32 μM). NT stands for non-treated control cells and is represented by
white bars.
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this class of drugs (Ersvaer et al., 2010; Fujiwara et al., 1998; Hong
et al., 2011; Lee et al., 2010; Warrilow et al., 2006). Ingenol-3-
angelate (referred to as PEP005) is derived from the plant
Euphorbia peplus and is currently in clinical trials for eradicating
basal cell carcinoma, actinic keratosis (a disease associated with
photo-damaged skin that may lead to invasive squamous cell
carcinoma) and squamous cell carcinoma (SCC) in situ by topical
application (Ersvaer et al., 2010; Li et al., 2010; Song et al., 2013).
Ingenol-3-angelate also shows pro-apoptotic effects in several
malignant cells, including melanoma cell lines and primary human
acute myelogenous leukemia cells (Ersvaer et al., 2010; Li et al.,
2010; Olsnes et al., 2009). Similar to ING B, PEP005 is a broad
range activator of the classical (α, β, γ) and novel (δ, ε, η, θ)
protein kinase C isoenzymes (Ersvaer et al., 2010) and is capable to
activate NF-κB (Olsnes et al., 2009). The results with PEP005 are
very promising and this drug is FDA approved for the topical
treatment of actinic keratoses (AK). Ingenol-3-angelate also inhi-
bits HIV infection by downmodulating CD4 and CXCR4 receptors
and enhances HIV-1 replication in chronically infected cells,
reiterating the clinical application of ingenol compounds to HIV
cure (Ersvaer et al., 2010; Hong et al., 2011; Olsnes et al., 2009).
Other important medical effects obtained using ingenol derivates
such as ingenol mebuate and ingenol 3,20-dibenzoate have been
published (Aditya and Gupta, 2013; Racke et al., 2012). Our com-
parison of ING B with the latter compound showed that ING B
was more efﬁcient in activating HIV from latency than ingenol
3,20-dibenzoate.
We demonstrated that the ING B action mechanism is based on
the activation of both classes of PKC isoforms: calcium dependent
and independent. Gö 6976 is a PKC inhibitor speciﬁc for Ca2þ
dependent (PKC-α and β) and Gö 6983 targets both classes (PKC-α,
PKC-β, PKC-γ, PKC-δ and PKC-ζ), similar to Ro-31–8220 that
inhibits PKC-α, PKC-β, PKC-ε and PKC-γ. All these inhibitors block
ING B activation, suggesting that this compound is a broad range
PKC agonist. These results were conﬁrmed by confocal microscopy
that showed that ING B treatment promotes translocation of
calcium dependent and independent PKC isoforms (PKC-α, PKC-γ
and PKC-δ) to the cytoplasmic membrane. PKC activation leads to
NF-κB nuclear translocation and this cellular factor appears to be
the key factor required for latent provirus reactivation (Bachu et al.,
2012; Spitaler and Cantrell, 2004; Steinberg, 2008; Torgerson
et al., 1998; Van Lint et al., 2013; Williams et al., 2004; Dahabieh
et al., 2014). We observed that constructs harboring deﬁcient
NF-κB binding sites in the HIV-LTR are not responsive to ING B
activation. Indeed, ING B was able to induce NF-κB nuclear
translocation regardless of HIV infection. Overall, LTR regions of
HIV subtype C presenting duplications of NF-kB binding sites were
more responsive to ING B transcription activation, if compared
with HIV LTR from subtype B viruses. These are promising and
innovative results concerning anti-latency agent activity in non-B
HIV subtypes. Our results suggest that HIV subtype C viruses can
potentially be more responsive to transcription activators com-
pounds that target NF-kB interaction. This aspect should be
considered in latency studies, since subtype C accounts for the
majority of worldwide infections (Rossenkhan et al., 2013).
The variation in the number of transcription factor-responsive
elements in the LTR promoter has been shown to differentially
regulate viral transcription and replication in a dose-dependent
manner upon exposure of HIV-infected cells to cytokines, such as
TNF-α (Montano et al., 2000; Opijnen et al., 2004). It is known that
a single NF-κB binding site is present in the promoter of HIV-1
subtype E (HIV-1E), yet subtype B contains two, with subtype C
containing at least three, but as many as four, NF-κB consensus
sequences (Bachu et al., 2012; Roof et al., 2002; Rossenkhan et al.,
2013). Moreover, Tat transactivation potential from different sub-
types is not uniform: for example, subtype E and C Tat are strong
Fig. 5. ING B compares favorably to other known compounds in HIV reactivation potential. J-Lat cells were treated with different transcriptional activators (ING B, PMA,
prostratin, SAHA and ingenol 3,20-dibenzoate) for 24 h. First, J-Lat 6.3 cells (A) and J-Lat 8.4 cells (B) were incubated with each compounds (PMA, prostratin, SAHA and
ingenol 3,20-dibenzoate) at 0.32 μM, which is the best concentration of ING B described and percentage of GFP positive cells was determined by FACS. Next, J-Lat 6.3 cells
(C) and J-Lat 8.4 cells (D) were incubated with optimal concentrations of each compound (PMA, 20 nM; prostratin, 10 μM; SAHA, 10 μM and ING B, 0.32 μM) and percentage
of GFP positive cells were also determined by FACS. Error bars represent the standard deviation of triplicate experiments.
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mediators of LTR transcription compared to subtype B, and this is
thought to be due to a higher afﬁnity for the TAR hairpin
(Desfosses et al., 2005). Tat half-life from subtype E is about twice
as long as that from subtypes B and C, which may be a compensa-
tory mechanism for the reduction in NF-κB binding sites
(Desfosses et al., 2005; Rossenkhan et al., 2013). All these reports
support the fact that prolonged high viremia has been shown in a
subset of patients during primary HIV-1 subtype C infection. It is
during this primary phase of infection that the reservoir of latently
infected, resting CD4þ T cells is established and anti-latency
potential candidates should be considered to restore complete
viral gene expression in subtype C infected patients.
ING B activates virus transcription in our ex vivo model using
primary human resting CD4þ T lymphocytes infected with HIV-1.
This result was even more striking when ING B was combined
with SAHA, suggesting an additive effect between these com-
pounds. Additive and synergistic activation generally occurs when
molecules act in different activation pathways. There are some
descriptions about synergism among reactivator compounds lead-
ing to higher levels of gene expression when used together
Fig. 6. ING B reactivates latent HIV-1 in primary CD4þ T cells. Naïve CD4þ T cells were isolated from three different healthy donors. CD4þ T cells were activated and
infected with an envelope defective HIV-1 virus and returned to a resting state by gradually reducing IL-2 concentration (30–2 U/ml) in the medium. Luciferase activity and
levels of activator markers CD38, CD69 and HLA-DR were measured before and at intermediate time points after infection. After resting, cells were stimulated with SAHA,
ING B or both. Luciferase activity was measured 24 and 48 h later. (A) Chronological representation of the entire experiment. (B) Average levels of CD38, CD69, HLA-DR and
luciferase activity at different time points are indicated. Error bars indicate the standard error of triplicate experiments. Black arrow below the graph indicates the point that
HIV infection was performed. (C) Reactivation levels of latent HIV-1 in the resting CD4þ T cells. ING B (1 mM) and SAHA (1 mM) were used alone or in combination as
indicated. Luciferase activity was analyzed 24 and 48 h after activation (white and black bars respectively) and is shown as fold change relative to non-treated cells (FC). Error
bars indicate the standard deviation of triplicate experiments.
Fig. 7. ING B induces higher levels of P-TEFb components in human primary cells. Naïve T CD4þ cells were isolated from three different healthy donors and treated with ING
B (1 mM) for 24 or 48 h. After these periods, P-TEFb components (Cyc T1 and CDK9) expression was analyzed. (A) Cyc T1 (top panel) and CDK9 (middle panel) proteins levels
were evaluated by immunoblotting of cell lysates from non-treated (mock) and ING B treated cells for 24 and 48 h. Tubulin (bottom panel) was used as loading control. Non-
treated cells are presented in the lines 1, 4 and 7. (B) Quantiﬁcation of the immunoblots from the three donors is shown as fold change (treated/non-treated cells ratio).
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(Remoli et al., 2012). It has been demonstrated that histone
deacetylase inhibitor and PKC agonist can work synergistically as
shown by SAHA and prostratin (Burnett et al., 2010; Reuse et al.,
2009). We hypothesized that PKC activation mediated by ING B in
addition with HDACi (SAHA) effects lead to a more robust activa-
tion of viral transcription. Nevertheless, some activator com-
pounds have failed to reactivate HIV in vivo (Bullen et al., 2014).
One effective single agent able to disrupt HIV latency in vivo was
the PKC agonist bryostatin-1, which is probably too toxic for
clinical use (Bullen et al., 2014). Overall, apparent clinical side
effects of latency-reversing agents such as PKC agonists adminis-
tration to patients include respiratory distress syndrome, hypoten-
sion, and other toxicities due to the release of pro-inﬂammatory
cytokines via non speciﬁc cellular activation (Maioli and Fortino,
2004; McKernan et al., 2012; Strair et al., 2002). The search for
other compounds that reactivate latent HIV, independently of
action pathway, and that can also be safely administered to
patients must proceed. Further progress may depend on ﬁnding
safe and active combinations of latency-reversing agents (Bullen
et al., 2014). Although our ﬁndings demonstrated safe cytotoxicity
proﬁle in vitro and ex vivo models with ING B we did not address
toxicity in animal models or for clinical treatment.
Additionally, both ING B and ingenol 3,20-dibenzoate could
induce differential expression of P-TEFb subunits, such as CDK9
and Cyc T1. Interestingly, we and others observed little effect on
HIV latency of HDAC inhibition in primary resting CD4þ cells
(Friedman et al., 2011; Sahu and Cloyd, 2011; Tyagi et al., 2010).
In these cells, levels of P-TEFb are particularly low due to actions of
speciﬁc miRNAs and NF-90, which block the translation of CycT1
mRNA (Bartholomeeusen et al., 2013; Hoque et al., 2011). Since
primary resting cells contain insigniﬁcant levels of P-TEFb, these
had to be increased ﬁrst with PKC agonists before effects of the
most potent HDACi, SAHA, could be observed. The effects of ING B
on P-TEFb could explain the results of additive effects of ING B
with SAHA to reactivate HIV from latency. This combination
doubled virus transcription compared to ING B treatment alone
and a ten-fold induction was detected compared to the induction
obtained with SAHA alone. These compounds could be admini-
strated together or sequentially to lower chromatin condensation
and release P-TEFb from its inactive complex. We envisage that if
ingenol is given ﬁrst, it would also lead to P-TEFb synthesis and
release, boosting SAHA's effect on HIV reactivation. It is important
to point out that the additive effect was not observed with the
close related molecule ingenol 3,20-dibenzoate, indicating that it
is not a feature shared by all ingenol compounds.
Conclusions
In our quest for an effective agent capable of reactivating latent
HIV reservoirs, we found a promising lead: 3-caproyl-ingenol (ING B).
HIV latency reactivators could be applied intermittently to the
patients undergoing anti-retroviral therapy. Based on the results
presented here, it would be expected that several rounds of
treatments with ING B would result either in complete elimination
of HIV or decrease in viral load to the point at which the immune
system could complete the elimination of this pathogen. Several
aspects favor ING B use as follows: (a) there would be abundant
source of ingenol since the Brazilian Euphorbia tirucalli is easily
grown in plantations; (b) ingenol derivatives have already been
used therapeutically in humans to tackle diseases (Aditya and
Gupta, 2013; Ersvaer et al., 2010) and their potential in HIV
activation has been largely described (Fujiwara et al., 1998;
Hong et al., 2011; Spitaler and Cantrell, 2004; Steinberg, 2008;
Van Lint et al., 2013); (c) we obtained a proof of principle that ING
B does reactivate latent HIV ex vivo. Additionally, this has also been
proven in a study with Rhesus macaque model where it was
shown that treatment with ING B could activate SIV mac 251
latency in Rhesus monkeys by oral administration and had an
excellent toxicity proﬁle (manuscript in preparation). All these
in vivo properties in non-human primate models added to the
molecular mechanisms of reactivation presented here, strongly
recommends 3-caproyl-ingenol (ingenol B, ING B) as a great
candidate for future clinical trials for HIV eradication.
Materials and methods
Cell lines
Jurkat, J-Lat 6.3, J-Lat 8.4 and Hella cells were obtained from
National Institute of Health (NIH). Primary cells were isolated from
healthy blood donors from Hemorio, Rio de Janeiro, Brazil. Jurkat,
J-Lat 6.3, J-Lat 8.4 and primary cells were grown in RPMI 1640
medium containing penicillin (100 IU/ml), streptomycin (100 g/
ml), and 10% fetal bovine serum at 37 1C with 5% CO2. Hella cells
were cultured in Dulbecco's modiﬁed Eagle's medium (DMEM)
containing the same supplements and conditions.
Reagents
The natural compound ingenol-3-dodecatrienoates extracted
from Euphorbiaceae and the derivate esters Ingenol A, B and C
were isolated by Kyolab Laboratories (São Paulo, Brazil). Ingenol
3,20-dibenzoate, PMA, prostatin and the PKC inhibitors Gö 6976,
Gö 6983 and Ro-31–8220 were obtained from Santa Cruz Biotech-
nology. SAHA was obtained from SelleckChem (Houston, USA). All
these compounds were diluted to speciﬁc concentrations in
DMEM or RPMI, and the ﬁnal concentration of solvent (DMSO)
was always less than 1%. We used 20 ng/ml of TNF-α (eBios-
ciences) as positive control of reactivation. Levels of P-TEFb
components were evaluated by immunoblotting using speciﬁc
antibodies anti-CDK9 and anti-Cyc T1 (Santa Cruz Biotechnologies,
cat. number 484 and 10750, respectively). Anti-tubulin (Abcam,
cat. number 56676) was used to normalize proteins level.
Latency reactivation and cell viability assays
J-Lat cells (clones 6.3 and 8.4) were used as HIV-1 latency
model. These cells harbor a HIV-GFP latent proviral clone inte-
grated in the genome (Jordan et al., 2003). The level of reactivation
was measured by ﬂow cytometry. Before expansion, cells were
treated with different concentrations of each compound, ING
(parent molecule), Ingenol A, B and C and ingenol 3,20-dibenzoate,
separately at different times. Cells (2105) were ﬁxed with
paraformaldehyde (2%) for 30 min at 4 1C followed by PBS wash-
ing. In the experiments involving PKC inhibitors, 1 μM of each
compound was separately added in the cell culture 24 h before the
treatment with ING B (0.32 μM). TNF-α (20 ng/ml) was used as
positive control. Flow cytometry analyses were performed 24 h
after ING B addition. Cell viability assays were performed using
Cell Titer Blue (Promega) following manufacturer's instructions.
Brieﬂy, J-Lat 6.3 and 8.4 (104 cells) were plated and treated with
each compound at different concentrations. Cell Titer Blue reagent
was added ﬁve days post-treatment and followed by overnight
incubation. Absorbance levels were evaluated by spectrophot-
ometer at 595 nm.
HIV-1 p24 antigen ELISA
J-Lat cells 6.3 and 8.4 were treated with ING B (0.32 μM) for
48 h. TNF-α (20 ng/ml) was used as positive control to particle
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release, for the same time of induction (48 h). Virus production
was evaluated by ELISA HIV-1 p24 antigen detection (Zeptometrix)
from culture supernatants. Absorbance levels were evaluated at
450 nm using a spectrophotometer.
Plasmids and site directed mutagenesis
The luciferase expressing vector (pBlue30 LTR-LUC B) was
obtained from NIH. This vector expresses ﬁreﬂy luciferase gene
under HIV-1 LTR control. Site directed mutagenesis at the two
NF-κB binding site of this same plasmid was performed using
Quick Change Lighting Multi Site Directed Mutagenesis (Strata-
gene), following manufacturer's instructions. The primers NF-κB
MutF - 50- CGA GCT TGC TAC AAG CGA CTT TCC GCT GGC GAC TTT
CCA GGG AGG -30 and NF-κB MutR - 50- CCT CCC TGG AAA GTC
GCC AGC GGA AAG TCG CTT GTA GCA AGC TCG -30 were designed
to perform the site directed mutagenesis. This pair of primers
changed the second guanine at both NF-κB binding sites into LTR
promoter to a cytosine, resulting in the plasmid designed here as
pBlue30LTR NF-κB MUT-Luc (NF-κB BS) lacking functional NF-κB
binding sites.
Transfections, ING B induction and luciferase assays
Jurkat cells (5105) were transiently transfected with 15 mg
of plamids pBlue30LTR-Luc wild type (WT) and pBlue30LTR NF-κB
MUT-Luc (NF-κB BS) using the Neon Transfection System (Life
Technologies) according manufacturer's instructions. After trans-
fections, cells were equally separated in two groups: treated and
non-treated with 0.32 mM of ING B. Luciferase assay was per-
formed 24 h after ING B induction. Cell lysates were obtained
using Luciferase Reporter Lysis Buffer (Promega) and the luciferase
activity measured using GloMax luminometer (Promega).
PKC activation and confocal microscopy
Three different plasmids coding for human PKC isoforms fused
with GFP reporter (PKCα-GFP, PKCδ-GFP and PKCγ-GFP) were
gently provided by Dr. Morgan Huse (Memorial Sloan-Katterin
Cancer Center, NY, USA). HeLa cells (2104) were grown in Black
96 Well Cell Culture Microplate (Corning) at 70–80% of conﬂuence.
Afterwards, transient transfection was performed with human
PKCα-GFP, PKCδ-GFP and PKCγ-GFP plasmids using Fugene HD
(Promega) according manufacturer's instructions. ING B (1 mM)
was added 24 h post transfection and the cells were ﬁxed with
paraformaldehyde (2%) at different times. Positive control was
performed using PMA (1 μM). The cells were washed with PBS and
submitted to DAPI staining. Finally, the sub-cellular localization of
PKC-GFP was evaluated using a High Content Screening confocal
microscope (Molecular Devices, Inc). GFP-positive cells (200 per
well) were counted using ImageJ software and the relative percen-
tage of PKC-activated cells were measured for each PKC isoform.
NF-κB nuclear translocation
HeLa cells (2104) were plated in Black 96 Well Cell Culture
Microplate (Corning). Cells were treated with 1 mM of PMA
(positive control) or ING B (1 mM). After induction, cells were ﬁxed
with paraformaldehyde (2%) at different times and immunoﬂuor-
escense assay was performed to endogenous subunits of NF-kB
using anti-p65 (1:300) (Santa Cruz Biotechnologies, cat. number
109). Nuclear staining was performed using DAPI. Finally, NF-κB
nuclear translocation was analyzed using the Translocator Module
of MetaXpress software of the High Content Screening confocal
microscope (Molecular Devices, Inc). Each treatment was per-
formed three times and about 800 cells in average were analyzed
per treatment. In order to detect NF-kB internalization the cells
were scored using DAPI staining and the NF-kB visualized using
Alexa Fluors 594 Donkey anti-Rabbit IgG (1:1000) secondary
antibody (Life Technologies, cat. number A-21207).
Transcription activation of reporter genes controlled by B and C LTR
subtypes
Four different constructs derivate from the dual-reporter vector
pLTR-sLuc-IRES-EGFP that simultaneously expresses two different
reporter genes, secreted Gaussia luciferase (sLuc) and enhanced
green ﬂuorescent protein (EGFP), were gently provided for
Dr. Udaykumar Ranga (HIV-AIDS Laboratory, Molecular Biology
and Genetics Unit, Jawaharlal Nehru Centre for Advanced Scientiﬁc
Research, Bengaluru, India). The ﬁrst construct comprises a typical B
LTR, and was called B-LTR (NL-43). The second one comprises a
typical C LTR derivate for a HIV subtype C from India, described here
as C-LTR (Indie1). Typically, LTR from HIV C-subtype comprises
three NF-κB binding sites. A third construct comprises a
C-LTR with four NF-κB binding sites was designated as FHHC-LTR.
The forth one was designated null mutant been a LTR carrying no
NF-κB binding site. All constructs were previously described (Bachu
et al., 2012). Jurkat cells were transfected with all these construc-
tions separately by electroporation. Six hours post transfections the
cells were separated in two groups (treated or not-treated) and
submitted to the following treatments: PMA (1 μM), TNF-α (20 ng/
ml) or ING B (0.32 μM). The cells lysates were obtained 24 h post
treatment and the luciferase activity evaluated using the Gaussia
Luciferase kit (New England BioLabs) (Bachu et al., 2012).
Transcription activation in primary cells
Buffy coat from different healthy adults were obtained from
Hemorio Blood Bank, Rio de Janeiro, Brazil. PBMC was isolated using
Ficoll Paque Plus (GE Lifesciences), according to manufacturer's
instructions. Cells were grown in RPMI 1640 medium containing
penicillin (100 IU/ml), streptomycin (100 g/ml), and 10% fetal bovine
serum at 37 1C with 5% CO2. Isolated PBMCs from three different
donors were separately transfected with pBlue3´LTR-Luciferase B
(WT) using Neon Transfection System (Life Technologies) according
manufacturer's instructions, using the following conditions: 12 mg
of plasmid were mixed to 106 cells and after that, cells were
exposed to one pulse with 20 ms of width and voltage of 2,150 V.
After transfections, cells were separated in two groups: non-treated
and treated with ING B (1 mM). Luciferase assays were performed
24 h after treatments, as described above.
Activation markers analyses
For analysis of cellular activation marker expression, enrich-
ment T CD4þ cells from human PBMCs were incubated with 1 μM
of each compound (ING B, PMA and prostratin) at 37 1C for 48 h.
After incubation, cells were washed with PBS and incubated for
20 min at room temperature with antibodies against CD69-Paciﬁc
Blue (clone FN50 – BD Biosciences), CD38-FITC (clone AT-1 – Stem
Cell Technologies), and HLA-DR-Qdot 605 (clone TÜ36 – Life
Technologies). Activation markers were evaluated on a LSR Fortessa
cytometer (BD Biosciences). Data analysis was performed using
FlowJo software (Tree Star).
Preparation, infection, resting and reactivation of primary CD4þ T
cells
Buffy coat from different healthy adults were obtained from
Hemorio Blood Bank, Rio de Janeiro, Brazil. PBMC was isolated using
Ficoll Paque Plus (GE Lifesciences), according to manufacturer's
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instructions. Naïve CD4þ T cells were puriﬁed using the Dynabeadss
Untouched™ Human CD4 T Cells kit (Invitrogen) according to the
manufacturer's protocol. CD4þ T cells were maintained in RPMI, 10%
FBS, 30 U/ml IL-2 at 37 1C with 5% CO2 for 24 h. After this period, cells
were activated using anti-CD3/anti-CD28 Dynabeads (Invitrogen) and
maintained for 5 days in RPMI with the same conditions above
described. Purity and activation levels were determined by FACS
analysis using speciﬁc antibodies against CD4, CD69 and HLA-DR
(BD Biosciences). Activated CD4þT cells were infected by spin
inoculation using a luciferase reporter virus pseudotyped with HIV
envelope proteins (pNL4.3ΔenvΔNef-Luc). To produce this pseudo-
typed virus HEK-293T cells were transfected by Fugene HD (Promega)
using the pNL4.3ΔenvΔNef-Luc and pEnvHIV at 1:3 proportion. The
pEnvHIV plasmid was kindly provided by Dr. Kotaro Shirakawa. The
virus was previously titrated in Jurkat cells and we used about 200 ng
of p24 to infect the Naïve CD4þ Tcells. Cells were reverted to a resting
state by gradually decreasing the amount of IL-2 in the medium to
2 U/ml over the period of 12 days. Luciferase activity was measured
over this period until they reached a background plateau. After this
period, reactivation treatment with the following drugs alone or
conjugated in different concentrations was performed for 24 and
48 h: ING B (1 mM), SAHA (330 and 1000mM), HMBA (330 and
3000 mM) and ingenol 3,20 dibenzoate (20 nM). HIV lantency reacti-
vation was detected by luciferase activity as previously described.
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